Latest From Genexine Inc.
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.
From being generics-focused to becoming innovators and leaders in biosimilars, Scrip takes a look at how the Korean pharma sector and environment have evolved over the past 10 years.
The South Korean pharma/biotech industry suffered a series of negative blows in 2019 but there were still notable achievements including major drug approvals and large-scale licensing deals.
Daiichi Sankyo obtains rights to antiemetic Nasea and the anti-hypertension drugs Perdipine and Oldeca. Mitsubishi Tanabe licenses Asian rights to Viela’s inebilizumab for a rare eye disorder.
- Large Molecule
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Infectious & Viral Diseases
- Metabolic Disorders
- Genexine Co. Ltd.
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Genexine Inc.
- Senior Management
Young Chul Sung , PhD, CTO
Tae Kim, PhD, VP, Clin. Operations
Kyudon Kim, EVP, COO
- Contact Info
Phone: (82) 31 628 3200
700 Daewangpangyo-ro, Korea Bio Park
Bundang-gu, Seongnam-si,, 13488
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.